Thông tin thuốc gốc
Chỉ định và Liều dùng
HIV infection
Adult: 150 mg bid or 300 mg once daily, in combination w/ other antiretrovirals.
Child: As soln: >3 mth <14 kg: 4 mg/kg bid. As tab: 14-21 kg: 75 mg bid; 22-30 kg: 75 mg in the morning and 150 mg at night; >30 kg: 150 mg bid. Max: 300 mg daily. Doses are given in combination w/ other antiretrovirals.

Chronic hepatitis B
Adult: 100 mg once daily. For patients w/ concomitant HIV infection: 150 mg bid or 300 mg once daily.
Child: 2-17 yr 3 mg/kg once daily. Max: 100 mg daily.
Suy thận
Chronic hepatitis B:
CrCl (mL/min) Dosage
<5 1st dose 35 mg, then 10 mg once daily.
5-14 1st dose 35 mg, then 15 mg once daily.
15-29 1st dose 100 mg, then 25 mg once daily.
30-49 1st dose 100 mg, then 50 mg once daily.

HIV infection:
CrCl (mL/min) Dosage
<5 1st dose 50 mg, then 25 mg once daily.
5-14 1st dose 150 mg, then 50 mg once daily.
15-29 1st dose 150 mg, then 100 mg once daily.
30-49 1st dose 150 mg, then 150 mg once daily.
Cách dùng
May be taken with or without food.
Chống chỉ định
Hypersensitivity. Lactation.
Thận trọng
Patient w/ hepatomegaly, hepatitis or other risk factors for hepatic disease; childn w/ history or risk factors for pancreatitis. Pregnancy.
Tác dụng không mong muốn
Abdominal pain, nausea, vomiting, diarrhoea, headache, fever, rash, alopecia, malaise, insomnia, cough, nasal symptoms, arthralgia, musculoskeletal pain, pancreatitis, anaemia, neutropenia, thrombocytopenia, immune reconstitution syndrome, lipodystrophy, metabolic abnormalities (e.g. hypertriglyceridaemia, hypercholesterolaemia, insulin resistance, hyperglycaemia, hyperlactataemia), osteonecrosis; increased creatine phosphokinase, liver enzymes and serum amylase. Rarely, rhabdomyolysis.
Potentially Fatal: Lactic acidosis, hepatomegaly w/ steatosis.
Chỉ số theo dõi
Monitor amylase, bilirubin, liver enzymes 3 mthly during therapy; haematologic parameters, HIV viral load, CD4 count; signs and symptoms of pancreatitis or hepatonecroinflammation; hepatitis B virus (HBV) DNA regularly during therapy. Monitor hepatic function for several mth following discontinuation of therapy. Perform HIV testing prior to and periodically during treatment.
Tương tác
Decreased renal excretion w/ high-dose trimethoprim. Severe anaemia may occur when used concomitantly w/ zidovudine. Treatment failure and emergence of resistance may result from once daily triple regimens of lamivudine and tenofovir w/ either abacavir or didanosine. May antagonise the antiviral action of zalcitabine. May enhance the adverse effect of emtricitabine.
Tương tác với thức ăn
Food decreases rate of absorption.
Tác dụng
Mechanism of Action: Lamivudine, a synthetic nucleoside analogue, is phosphorylated into the body to the active 5'-triphosphate metabolite. It inhibits RNA- and DNA-dependent polymerase activities of reverse transcriptase via DNA chain termination.
Absorption: Rapidly absorbed from the GI tract. Delayed absorption by ingestion w/ food. Bioavailability: 80-87%. Time to peak plasma concentration: Approx 1 hr.
Distribution: Crosses the blood-brain barrier and placenta; enters breast milk. Volume of distribution: 1.3 L/kg. Plasma protein binding: Up to 36%.
Metabolism: Metabolised intracellularly to the active metabolite lamivudine triphosphate via phosphorylation.
Excretion: Via urine, mainly as unchanged drug. Elimination half-life: 5-7 hr.
Đặc tính

Chemical Structure Image

Source: National Center for Biotechnology Information. PubChem Database. Lamivudine, CID=60825, (accessed on Jan. 22, 2020)

Bảo quản
Store between 20-25°C.
Phân loại MIMS
Thuốc kháng virus
Phân loại ATC
J05AF05 - lamivudine ; Belongs to the class of nucleoside and nucleotide reverse transcriptase inhibitors. Used in the systemic treatment of viral infections.
Tài liệu tham khảo
Anon. Lamivudine. Lexicomp Online. Hudson, Ohio. Wolters Kluwer Clinical Drug Information, Inc. Accessed 15/09/2015.

Buckingham R (ed). Lamivudine. Martindale: The Complete Drug Reference [online]. London. Pharmaceutical Press. Accessed 15/09/2015.

Lamivudine Tablet, Film coated (Mylan Pharmaceuticals Inc). DailyMed. Source: U.S. National Library of Medicine. Accessed 15/09/2015.

Thông báo miễn trừ trách nhiệm: Thông tin này được MIMS biên soạn một cách độc lập dựa trên thông tin của Lamivudine từ nhiều nguồn tài liệu tham khảo và được cung cấp chỉ cho mục đích tham khảo. Việc sử dụng điều trị và thông tin kê toa có thể khác nhau giữa các quốc gia. Vui lòng tham khảo thông tin sản phẩm trong MIMS để biết thông tin kê toa cụ thể đã qua phê duyệt ở quốc gia đó. Mặc dù đã rất nỗ lực để đảm bảo nội dung được chính xác nhưng MIMS sẽ không chịu trách nhiệm hoặc nghĩa vụ pháp lý cho bất kỳ yêu cầu bồi thường hay thiệt hại nào phát sinh do việc sử dụng hoặc sử dụng sai các thông tin ở đây, về nội dung thông tin hoặc về sự thiếu sót thông tin, hoặc về thông tin khác. © 2024 MIMS. Bản quyền thuộc về MIMS. Phát triển bởi
  • Antiheb
  • Avudine
  • Axolam
  • Bephardin
  • Bilavir
  • DevudinSPM
  • Epivir
  • Glamivir
  • Hepavudin
  • Hivir
  • Hivuladin
  • Ikolam
  • Ladinex
  • Lamidac 100
  • Lamiffix
  • Lamijas
  • Laminova
  • Lamivudin 100 ICA
  • Lamivudin 150 ICA
  • Lamivudin Domesco 100 mg
  • Lamivudin Domesco 150 mg
  • Lamivudin Hasan
  • Lamivudin Pharimexco
  • Lamivudine Tablets
  • Lamovin
  • Lapuvir
  • Larevir
  • Laviz
  • Lavusafe
  • Lazzy
  • Lemidina
  • Loramide
  • Mevudine
  • Pilafix
  • Retrocytin
  • Tabvudin
  • Timivudin
  • Tizacure
  • TV-Ladine
  • Victron
  • Vifix
  • Vigapro
  • Vinradin
  • Virolam
  • Zefdavir
  • Zeffix
  • Zymmex
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Already a member? Sign in